Visterra, Serum Institute of India deal

Visterra granted Serum an exclusive license to develop and commercialize preclinical Dengue fever compound VIS513 in India, Pakistan, Bangladesh, Nepal, Bhutan, Maldives and Sri Lanka. Visterra will receive a $5 million upfront payment and is eligible for up to $34 million in development and commercialization milestones, plus tiered double-digit royalties. ...